Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

37.83USD
13 Jan 2017
Change (% chg)

$1.10 (+2.99%)
Prev Close
$36.73
Open
$36.57
Day's High
$38.55
Day's Low
$36.57
Volume
2,649,563
Avg. Vol
3,923,688
52-wk High
$63.73
52-wk Low
$8.00

Select another date:

Tue, Jan 10 2017

BRIEF-Sarepta Therapeutics enters into license agreement with nationwide children's hospital

* Sarepta Therapeutics enters into license agreement with nationwide children's hospital for GALGT2 gene therapy program Source text for Eikon: Further company coverage:

BRIEF-Sarepta Therapeutics Q3 loss per share $1.18

* Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments

Anthem won't cover first FDA-approved Duchenne drug

Oct 7 Health insurer Anthem Inc said it would not cover the first U.S. Food and Drug Administration-approved Duchenne muscular dystrophy (DMD) drug, developed by Sarepta Therapeutics Inc, calling it "investigational and not medically necessary".

Sarepta partners with UK's Summit on Duchenne drugs

Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

UPDATE 3-Sarepta partners with UK's Summit on Duchenne drugs

Oct 4 Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

BRIEF-Summit's agreement with Sarepta also contains a standstill provision

* Collaboration agreement with Sarepta also contains a standstill provision - SEC filing

BRIEF-Sarepta Therapeutics reports pricing of $300 million public offering of common stock

* Sarepta Therapeutics announces pricing of $300 million public offering of common stock

BRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock

* Sarepta Therapeutics announces proposed public offering of common stock

Bowing to pressure, FDA approves Sarepta's Duchenne drug

Bowing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.

UPDATE 3-Bowing to pressure, U.S. FDA approves Sarepta's Duchenne drug

Sept 19 Bowing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.

Select another date: